Fate Therapeutics has patented a method for manufacturing induced immune regulatory cells, including myeloid suppressive cells, for treating various conditions. The method involves obtaining induced definitive hemogenic endothelium cells and directing their differentiation with specific factors to enhance therapeutic potential. GlobalData’s report on Fate Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Fate Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Fate Therapeutics, T-cell culturing was a key innovation area identified from patents. Fate Therapeutics's grant share as of February 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.

Method for generating immune regulatory cells with enhanced potential

Source: United States Patent and Trademark Office (USPTO). Credit: Fate Therapeutics Inc

A recently granted patent (Publication Number: US11851677B2) discloses an in vitro method for generating induced immune regulatory cells with enhanced therapeutic potential. The method involves obtaining induced definitive hemogenic endothelium cells (iHE) and directing their differentiation with a specific medium composition containing a ROCK inhibitor, GMCSF, and MCSF. This process results in a population of induced immune regulatory cells, including induced myeloid suppressive cells that are CD45+ and CD33+, showcasing improved therapeutic capabilities compared to conventional myeloid suppressive cells.

Furthermore, the patent details additional aspects of the method, such as the inclusion of various growth factors and cytokines in the medium composition, the specific subpopulations of induced myeloid suppressive cells present, and the genetic modifications that can be introduced to enhance the therapeutic potential of the cells. The method also involves genomic editing of the induced myeloid suppressive cells and the use of modulating agents to further enhance their therapeutic properties. Overall, the patent highlights a comprehensive approach to generating induced immune regulatory cells with specific characteristics and functionalities, paving the way for potential advancements in immunotherapy and related fields.

To know more about GlobalData’s detailed insights on Fate Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies